Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OCUL Ocular Therapeutix Inc
- Stocks
- Healthcare
- NASDAQ: OCUL
Price (delayed)
$8.38
Market cap
$1.33B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$1.06B
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation
Highlights
The company's EPS rose by 7% QoQ but it fell by 2.7% YoY
The net income has dropped by 67% year-on-year
Ocular Therapeutix's quick ratio has shrunk by 53% YoY and by 3.6% QoQ
Key stats
What are the main financial stats of OCUL
Market
Valuations
Earnings
Shares outstanding
159.3M
Market cap
$1.33B
Enterprise value
$1.06B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.01
Price to sales (P/S)
23.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.77
Revenue
$59.65M
Gross profit
$54.08M
Operating income
-$204.08M
Net income
-$192.71M
EBIT
-$180.2M
EBITDA
-$176.35M
Free cash flow
-$148.43M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.14
Free cash flow per share
-$0.88
Book value per share
$1.67
Revenue per share
$0.35
TBVPS
$2.4
Total assets
$405.92M
Total liabilities
$139.99M
Debt
$76.22M
Equity
$265.93M
Working capital
$349.77M
Debt to equity
0.29
Current ratio
10.22
Quick ratio
9.93
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
-295.7%
Gross margin
90.7%
Net margin
-323.1%
Operating margin
-342.2%
Return on assets
-41.2%
Return on equity
-58.8%
Return on invested capital
-183.6%
Return on capital employed
-49%
Return on sales
-302.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCUL stock price
How has the Ocular Therapeutix stock price performed over time
Intraday
0.6%
1 week
6.21%
1 month
-4.77%
1 year
58.11%
YTD
-1.87%
QTD
14.32%
Financial performance
How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$59.65M
Gross profit
$54.08M
Operating income
-$204.08M
Net income
-$192.71M
Gross margin
90.7%
Net margin
-323.1%
Ocular Therapeutix's operating margin has plunged by 124% YoY and by 27% from the previous quarter
The operating income has plunged by 123% YoY and by 19% from the previous quarter
The net margin has plunged by 68% YoY and by 6% from the previous quarter
The net income has dropped by 67% year-on-year
Price vs fundamentals
How does OCUL's price correlate with its fundamentals
Growth
What is Ocular Therapeutix's growth rate over time
Valuation
What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
5.01
P/S
23.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.77
The company's EPS rose by 7% QoQ but it fell by 2.7% YoY
OCUL's price to book (P/B) is 76% less than its 5-year quarterly average of 20.8 but 32% more than its last 4 quarters average of 3.8
The equity has declined by 35% year-on-year and by 16% since the previous quarter
The stock's P/S is 13% above its last 4 quarters average of 21.1 and 4.8% above its 5-year quarterly average of 22.7
The revenue has contracted by 6% from the previous quarter
Efficiency
How efficient is Ocular Therapeutix business performance
The company's return on sales has shrunk by 78% YoY and by 7% QoQ
OCUL's return on invested capital has dropped by 77% year-on-year and by 3.1% since the previous quarter
Ocular Therapeutix's return on equity has increased by 35% YoY but it has decreased by 10% QoQ
The return on assets has declined by 7% since the previous quarter but it has grown by 4% year-on-year
Dividends
What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCUL.
Financial health
How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets is 190% higher than its total liabilities
Ocular Therapeutix's quick ratio has shrunk by 53% YoY and by 3.6% QoQ
The current ratio has plunged by 52% YoY and by 4.1% from the previous quarter
The debt is 71% less than the equity
The company's debt to equity has surged by 61% YoY and by 21% QoQ
The equity has declined by 35% year-on-year and by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.